Price reduction of medicinal materials is conducive to the improvement of the performance of Chinese patent medicine companies

Source: on July 10, 2014, Guangzhou Daily, it was not only liquor and other fast-moving products that were hard to bear in the heat, but also a number of Chinese herbal medicines Our reporter exclusively interviewed and combed and found that, under the leadership of "big brother" such as Cordyceps, dangshen, angelica, etc., the drug market in the first half of this year has always been depressed, and the prices of many varieties have plummeted Reflected in the performance of listed companies, leading enterprises are under more pressure, with exclusive varieties of small and medium-sized pharmaceutical enterprises or more "favored" Fortunately, the industry believes that the market will be better in the future as the positive signs gradually appear "Since the opening of the market this year, the drug market has been in a general downturn, with a year-on-year decline in transactions The prices of many varieties have been hovering at low levels, and the prices of some varieties, such as Dangshen and Danggui, have declined significantly, which is not as good as the previous years." Zhang Bin, an analyst at Zhuo Chuang information, said "This year's production of Cordyceps has ended, and the recent market has rebounded relatively in the early stage The current market price of Tibet's 4000 high-quality products is 140000-145000 yuan, 1800-2000 products are 250000-260000 yuan, and the scraps are 90000-100000 yuan It is estimated that the future market is difficult to decline sharply " An industry observer told our reporter "One of the opportunities this year is the dividend from lower costs," he said A private equity source told our reporter earlier this year In the first quarter of this year, the company's performance increased by 77.22% In the past several consecutive quarters, the company's performance has declined significantly, among which, the net profit attributable to listed companies in 2013 decreased by 21.45% year-on-year and 71.39% in the first quarter of 2013 Last year, it fell 88.08% Furui said that the raw materials of the company's main business drugs include natural Cordyceps, turtle shell, Panax notoginseng, forsythia, etc., among which Cordyceps is the main raw material of compound turtle shell soft liver tablet, the leading drug of Furui Operating profit increased by 132.78% in response to the sharp rise in the first quarter of this year The company's Dong Mi Lin Xin revealed last month that the price of Cordyceps has dropped significantly since this year It is understood that most of the listed companies are expected to achieve good results in the semi annual report According to Furui, the net profit in the first half of this year is likely to increase significantly; the net profit growth of Guizhou bailing in the same period is likely to reach 30% Huang Fan, an analyst at Dongguan securities, pointed out that in 2013, the revenue of proprietary Chinese medicine increased by 20.31% and the net profit increased by 25.45% The advantages of traditional Chinese medicine injection are more obvious and the medium and long-term prospects are promising However, Huang Fan believes that under the pressure of medical insurance fee control and bidding price reduction, the slowdown of industry growth will be a long-term trend Some companies are still looking for breakthroughs in raw materials Our reporter learned from the scientific and Technological Innovation Conference held by dong'a-jiao on the 6th that, due to the shortage of donkey hide raw materials for a long time, the company is carrying out small molecular transformation of traditional donkey hide by grafting modern biotechnology to solve this contradiction In the secondary market, stock price differentiation is obvious, Yunnan Baiyao, Tianshili and other star stocks have declined by more than 10% this year Some insiders said that, from the basic point of view, the future profitability of Chinese patent medicine will be good, especially the small and medium-sized pharmaceutical industry with exclusive varieties may be more favored by the funds Reporters found that the same Chinese medicine enterprises, but the secondary market share prices are very different, among them, Yunnan Baiyao, Tianshili, pianzehuang and other well-known old Chinese medicine stocks are weak Most small and medium-sized traditional Chinese medicine enterprises are favored by funds, and Kangzhi pharmaceutical, an individual stock of gem, has risen 61.11% in the year Wohua pharmaceutical of small and medium-sized board also rose 30.45%, and Yibai pharmaceutical rose 27.07% In addition, Kangyuan pharmaceutical, Guizhou bailing, HongRi pharmaceutical and Tailong pharmaceutical all performed well Some institutional analysts of traditional Chinese medicine stock differentiation pointed out that under the declining trend of common drug prices, "whether the decline of raw materials can make up for the gap in drug prices remains to be concerned." But for those small and medium-sized pharmaceutical industries with exclusive varieties, the market attention is still very high Because, these enterprises may be big enterprises Compared with the formed Yunnan Baiyao and other giants, it has more long-term investment value " An analyst in the pharmaceutical industry at a securities firm, who declined to be identified, told reporters Huang Fan also suggested that investors should pay attention to Chinese patent medicines with high prosperity, such as Xiangxue pharmaceutical, tag pharmaceutical, etc